查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1828009

疫苗契約製造市場（按疫苗類型、技術平台、服務提供、應用類型、使用階段和最終用戶分類）—2025-2032 年全球預測

Vaccine Contract Manufacturing Market by Vaccine Type, Technology Platform, Service Offering, Application Type, Application Stage, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，疫苗契約製造市場將成長至 114.3 億美元，複合年成長率為 9.53%。

主要市場統計數據
基準年2024年 55.1億美元
預計2025年 60.4億美元
預測年份：2032年 114.3億美元
複合年成長率（%） 9.53%

策略方向將疫苗契約製造定位為塑造公共衛生成果、商業化速度和跨境韌性的關鍵能力

疫苗契約製造領域正從單一的供應解決方案演變為涵蓋全球公共衛生、商業性藥物開發和地緣政治韌性的策略軸心。製造商、開發商和政策領導者擴大將製造外包視為一種可配置的能力，它可以決定專案時間表、監管風險和患者可及性。因此，決策者需要一種整合的觀點，將技術能力與製劑、填充、分析表徵和物流環節的服務編配連結起來。

本導言強調了技術進步、監管預期和地緣政治壓力如何共同創造風險和機遇，為建構綜合觀點鋪平了道路。它概述了影響合作夥伴選擇和能力投資的關鍵因素：疫苗模式多樣性、平台複雜性、服務範圍、臨床和商業階段要求以及最終用戶優先順序。將營運能力與策略成果掛鉤有助於經營團隊確定近期行動的優先順序（例如，確保雙源供應鏈或加速一次性系統的檢驗）。從認知到結構化決策的轉變需要清楚地了解科學、監管和物流之間的相互作用。

技術創新、監管敏捷性和綜合服務模式如何重新定義疫苗受託製造的競爭優勢

過去五年，製造業和研究服務的採購方式發生了翻天覆地的變化。 mRNA 和病毒載體平台架構的進步、模組化和一次性設施架構的日益普及，以及細胞技術和非細胞技術的興起，拓展了可行的專案設計範圍。這些技術變革也帶來了營運方面的進步：更複雜的分析技術正在縮短開發週期，灌裝-完成自動化正在降低差異性並加快規模化生產。

同時，監管機構正在採取更具適應性的審查路徑，並展現出依賴真實世界數據來支持核准後監測的意願。這些監管變革正推動申辦方和製造商共同製定基於特定場地、數據主導的驗證策略。市場參與企業正透過建立更深層、以能力主導的夥伴關係（而非一次性交易安排）來應對這項挑戰。因此，受託製造製造商正在上游工程拓展，涵蓋原料藥藥營運、製劑開發和整合分析等領域，成為全生命週期合作夥伴。總而言之，這些轉變創造了一個全新的競爭環境，其中技術敏捷性、監管熟悉度和服務整合決定了競爭優勢和專案韌性。

評估美國近期關稅變化如何改變疫苗生產的籌資策略、供應商合格和區域投資決策

美國新的貿易政策和關稅方案帶來了新的成本和營運考量，並波及全球供應鏈。關稅相關的摩擦正在推高進口原料、一次性零件和專用器械的總到岸成本，促使申辦方和製造商重新評估籌資策略。為此，醫療保健機構正在多元化其供應商基礎，尋找關鍵投入的本地替代方案，並加快庫存規劃以確保專案的連續性。

關稅也影響資本投資位置決策。投資者和策略團隊正在權衡近岸和在岸產能的韌性與現有離岸產能的固定成本優勢。這種考量促使人們開始關注建立區域樞紐，以降低跨境貿易政策波動帶來的風險，同時保持對熟練勞動力資源的取得和對監管的熟悉。同時，契約製造製造商正在提高供應鏈透明度，並投資於採購能力，以減輕關稅的影響。此類營運響應措施降低了專案突然中斷的可能性，使專案發起方能夠盡可能採用多模態物流和在地採購策略來確保專案按時完成。

深度細分主導的洞察，將疫苗模式、平台架構、服務產品、應用階段和最終用戶行為映射到夥伴關係和投資選擇

細緻的細分視角能夠清楚揭示策略價值所在以及能力差距所在。在分析疫苗多樣性（DNA疫苗、去活化疫苗、減毒疫苗、mRNA疫苗、類毒素疫苗、病毒載體疫苗）時，每種疫苗的上下游加工需求和監管環節均有所不同，這要求各組織將技術需求與生產專業知識結合。細胞培養方法分為貼壁細胞培養和懸浮細胞培養，而無細胞、卵子和合成胜肽平台則面臨獨特的規模化生產和分析挑戰。

分析服務、原料藥 (API) 製造、填充和封口、配方服務、分銷和包裝各自都需要獨特的能力和品質系統。預防性疫苗和治療性疫苗應用之間的差異會影響批次放行策略、滴度測定和上市後研究途徑。臨床階段專案需要靈活的製造和快速的變更管理，涵蓋 I、II 和 III 期研究；而商業階段專案則需要高效的能力、永續的供應協議和成熟的品管系統。最後，最終用戶類別（生物技術公司、政府機構和製藥公司）具有不同的採購行為、風險接受度和合約偏好，這些因素決定了商業合約結構和預期的技術轉移。

區域能力、監管多樣性和供應鏈走廊將決定疫苗製造投資將在何處提供戰略彈性和商業性優勢。

區域動態決定了在產能和能力方面的投資將在何處產生最大的策略回報。在美洲，快速取得先進的生技藥品平台是當務之急，而透過同地技術團隊和強大的分析能力來加速開發進度的夥伴關係往往更受青睞。該地區的監管事務強調與國際標準接軌，並通常支持優先項目的早期取得。

歐洲、中東和非洲呈現出多元化的監管和商業格局，靈活且區域分散的製造地備受青睞。這些地區的協調努力和跨境採購計畫使策略合作更具吸引力，尤其是在政府和機構尋求增強韌性的情況下。亞太市場參與企業重視可擴展的平台、經濟高效的生產以及日益成熟的合約開發和製造組織。從區域分析到行動，需要了解當地監管預期、勞動力可用性和物流走廊如何與技術選擇和長期供應協議相互交織。

策略行動、能力投資和夥伴關係模式，使疫苗生產領域的高績效契約製造製造商和服務供應商脫穎而出

疫苗受託製造領域公司之間的競爭動態取決於其在垂直整合、平台專業化和服務廣度方面的策略投資。領先的開發商透過整合分析服務和開發專業知識來減少技術轉移摩擦並加快臨床開發時間，從而實現差異化。其他公司則專注於模組化產能和靈活的一次性生產，使其無需大規模改造即可應對更廣泛的生產模式。聯盟和策略夥伴關係，從產能共用協議到技術授權和合資模式，是縮小能力差距和加速進入新市場的常用機制。

在能力層面，那些在灌裝-封口、強大的低溫運輸物流和檢驗的配方方法方面表現出穩定品質表現的公司，能夠獲得主要贊助商和公共採購商的優先合約。對數位化品質系統和資料完整性框架的投資已成為不可或缺的差異化因素，因為它們可以簡化遠端審核以及與監管機構的互動。從商業性角度來看，提供客製化合約條款（例如靈活的產能預留、基於里程碑的付款和風險共用模式）的組織更有可能贏得同樣重視速度和可預測性的專案。因此，競爭格局不僅獎勵技術卓越，也獎勵商業性創造力和營運透明度。

為協調技術力、供應鏈彈性、承包模式和區域參與以加速疫苗計劃的成功而提出的可行建議。

為了將洞察轉化為競爭優勢，產業領導者應專注於有針對性的可操作步驟，以降低專案風險並加速商業性進程。首先，優先考慮產能匹配，將疫苗模式和研發階段與合作夥伴的專業知識相匹配。其次，透過對關鍵原料和一次性組件的多家供應商進行資格審查，並制定包括區域採購和庫存緩衝在內的緊急時應對計畫，增強供應鏈的穩健性。

從營運角度來看，投資模組化設施設計和填充-封口自動化系統，可在不相應增加佔地面積或人員的情況下提高產量。從商業性角度來看，建立兼顧靈活性和可預測性的契約，將產能預留與基於績效的里程碑相結合。領導者還應投資分析和數位品質系統，以實現遠端監控、更快的批次放行和更順暢的監管提交。最後，在重點地區與當地相關人員建立選擇性夥伴關係關係，以降低關稅風險並加速市場准入。實施這些建議需要研發、供應鏈、品質和商業團隊之間的跨職能協調，但這樣做將顯著提高專案的韌性和上市時間。

透明的混合方法研究設計，結合主要相關人員訪談、監管和技術證據以及交叉檢驗綜合，為戰略決策提供資訊

這些見解背後的研究採用了混合方法，旨在對來自多個資料來源和相關人員觀點的證據進行三角測量。主要數據是透過受託製造廠商的高層領導進行結構化訪談收集的，旨在了解營運現狀和戰略重點。二級資訊來源包括同行評審文獻、監管指導文件、專利態勢和公司技術揭露，以檢驗有關技術趨勢和能力的主張。

透過交叉檢驗流程級證據和定性輸入（例如標準作業程式、監管提交範本和技術轉移案例研究）實現了分析的嚴謹性。資料品質保障措施包括訪談編碼、方法和資料來源的透明度以及排除無法透過至少兩個獨立資訊來源證實的聲明。這種方法強調可複製性和可追溯性，以便可以從原始輸入到整合再到經營團隊建議，追溯有關細分、區域動態和關稅影響的結論。這種調查方法為決策者提供了採購、產能規劃和夥伴關係選擇的理由。

綜合策略要務，展現綜合能力設計、供應鏈彈性和夥伴關係關係如何影響計畫和公共衛生成果。

技術創新、監管現代化和地緣政治壓力的交匯，重新定義了疫苗契約製造的優先事項。成功的組織將能夠將特定平台的卓越性與一體化服務產品、強大的供應鏈策略以及地域性投資選擇相結合。本分析強調了將各種模式需求（從mRNA和病毒載體到基於蛋白質的平台）與合適的製造架構和分析能力相結合的重要性，同時還要考慮生物技術公司、政府機構和製藥公司的採購實際情況。

總而言之，實現疫苗生產的彈性和高效，關鍵在於制定平衡的策略，以降低關稅和供應鏈波動，利用靈活自動化的生產能力，並建立透明的商業夥伴關係關係。高階主管應將製造外包視為一種戰略能力，需要精心設計，而非單純購買。透過採取有針對性的綜合方法來選擇合作夥伴並進行能力投資，組織可以降低專案風險，縮短開發時間，並提高向患者和公共衛生系統提供產品供應的可預測性。

目錄

第1章 引言

第2章分析方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 疫情防治策略推動mRNA疫苗契約製造需求成長
  • 擴大生技公司與CMO之間的合作關係，以擴大個人化癌症疫苗的生產管道
  • 採用一次性生物反應器技術，提高疫苗生產的靈活性並降低交叉污染風險
  • 協調監管工作，簡化主要疫苗生產轄區的品質和合規要求
  • 為解決全球管瓶和注射器短缺問題並加速疫苗分發，對灌裝和封口能力的投資激增
  • 整合數位雙胞胎和即時分析，實現疫苗 CMO 設施的流程最佳化和預測性維護

第6章：美國關稅的累積影響（2025年）

第7章：人工智慧（AI）的累積影響（2025年）

第8章疫苗契約製造市場（依疫苗類型）

  • DNA
  • 失活
  • 活病毒疫苗
  • mRNA
  • 類毒素
  • 病毒載體

9. 疫苗契約製造市場（依技術平台）

  • 基於細胞
    • 貼壁細胞培養
    • 懸浮細胞培養
  • 自拍
  • 雞蛋為主
  • 合成胜肽

第 10 章疫苗契約製造市場（按服務提供）

  • 分析服務
  • 原料藥(API) 製造
  • 填充和整理
  • 製造服務
  • 分配
  • 包裝

第11章疫苗契約製造市場（依應用類型）

  • 預防性疫苗
  • 治療性疫苗

第12章疫苗契約製造市場（依使用階段）

  • 臨床分期
    • 第一階段
    • 第二階段
    • 第三階段
  • 市場啟動階段

第13章疫苗契約製造市場（按最終用戶）

  • 生技公司
  • 政府機構
  • 製藥公司

第14章疫苗契約製造市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章疫苗契約製造市場（按類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章疫苗契約製造市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • AbbVie Inc
    • Ajinomoto Co., Inc.
    • Aton（Shanghai）Biotech Co., Ltd.
    • Avid Bioservices, Inc.
    • Catalent, Inc.
    • Charles River Laboratories International, Inc.
    • CSL Limited
    • Curia Global, Inc.
    • Cytovance Biologics by Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
    • Emergent BioSolutions Inc.
    • FUJIFILM Diosynth Biotechnologies USA, Inc. by FUJIFILM Corporation
    • Gedeon Richter PLC
    • GlaxoSmithKline PLC
    • ICON PLC
    • IDT Biologika GmbH
    • KBI Biopharma, Inc. by JSR Corporation
    • Klocke Pharma-Service GmbH
    • Lonza Group Ltd.
    • Merck KGaA
    • Moderna, Inc.
    • Pfizer Inc.
    • Pharmaceutical Product Development by Thermo Fisher Scientific Inc.
    • Recipharm AB
    • Serum Institute of India
    • Vetter Pharma-Fertigung GmbH & Co. KG
Product Code: MRR-430D42AA0DC4

The Vaccine Contract Manufacturing Market is projected to grow by USD 11.43 billion at a CAGR of 9.53% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 5.51 billion
Estimated Year [2025] USD 6.04 billion
Forecast Year [2032] USD 11.43 billion
CAGR (%) 9.53%

A strategic orientation that frames vaccine contract manufacturing as a critical capability shaping public health outcomes, commercialization speed, and cross-border resilience

The vaccine contract manufacturing landscape has evolved from a narrowly focused supply solution into a strategic axis of global public health, commercial drug development, and geopolitical resilience. Manufacturers, developers, and policy leaders are increasingly treating contract manufacturing as a configurable capability that shapes program timelines, regulatory risk, and patient access. As a result, decision-makers need an integrated perspective that connects technological competency with service orchestration across formulation, fill-finish, analytical characterization, and logistics.

This introduction sets the stage for that integrated perspective by highlighting how technological advances, regulatory expectations, and geopolitical pressures together create both risk and opportunity. It outlines the critical vectors that influence partner selection and capability investment: vaccine modality diversity, platform complexity, service scope, clinical and commercial stage requirements, and end-user priorities. By linking operational capabilities to strategic outcomes, the narrative that follows helps executive teams prioritize near-term actions-such as securing dual-source supply chains or accelerating validation of single-use systems-while keeping sight of longer-term imperatives like regional manufacturing capacity and workforce continuity. Transitioning from awareness to structured decision-making requires clarity about the interplay between science, regulation, and logistics; the content that follows offers that clarity in actionable terms.

How technological innovation, regulatory agility, and integrated service models are redefining competitive advantage in contract vaccine manufacturing

The past five years have produced transformative shifts that are changing how organizations source manufacturing and scientific services. Advances in mRNA and viral vector platforms, greater acceptance of modular and single-use facility architectures, and the emergence of cell-based and cell-free technologies have expanded the palette of feasible program designs. These technical shifts are accompanied by operational advances: more sophisticated analytics shorten development cycles, and automation in fill-finish reduces variability and accelerates scale-up timelines.

Concurrently, regulatory authorities have signaled a willingness to adopt more adaptive review pathways and rely on real-world data to support post-authorization monitoring. This regulatory evolution encourages sponsors and manufacturers to co-develop validation strategies that are field-ready and data-driven. Market participants are responding by forming deeper, capability-driven partnerships rather than one-off transactional contracts. As a result, contract manufacturers are moving upstream into drug substance work, formulation development, and integrated analytics to become full lifecycle partners. Taken together, these shifts create a new playing field where technological agility, regulatory savvy, and service integration determine competitive advantage and program resilience.

Assessment of how recent United States tariff dynamics are reshaping procurement strategies, supplier qualification, and regional investment decisions across vaccine manufacturing

Emerging trade policies and tariff scenarios in the United States introduced new cost and operational considerations that reverberate across global supply chains. Tariff-related frictions increase the total landed cost of imported raw materials, single-use components, and specialized instrumentation, prompting sponsors and manufacturers to reassess sourcing strategies. In response, organizations are diversifying supplier bases, qualifying regional substitutes for critical inputs, and accelerating inventory planning to protect program continuity.

The tariffs also influence location decisions for capital investments. Investors and strategic teams now weigh the resilience benefits of near-shore or on-shore capacity against the fixed cost advantages of established offshore capabilities. This calculus has prompted greater interest in establishing regional hubs that reduce exposure to cross-border trade policy volatility while preserving access to skilled labor pools and regulatory familiarity. In parallel, contract manufacturers are enhancing supply chain transparency and investing in procurement capabilities to mitigate tariff impacts. These operational responses reduce the likelihood of sudden program interruptions and enable sponsors to maintain timelines by adopting multi-modal logistics and local sourcing strategies where feasible.

Deep segmentation-driven insights that map vaccine modalities, platform architectures, service offerings, application stages, and end-user behaviors to partnership and investment choices

A nuanced segmentation lens clarifies where strategic value is concentrated and where capability gaps persist. When analyzing vaccine type diversity-spanning DNA, inactivated, live attenuated, mRNA, toxoid, and viral vector modalities-organizations must align technical requirements with manufacturing specialization, because each modality carries distinct upstream and downstream process needs and regulatory touchpoints. Technology platforms further stratify requirements: cell-based approaches are divided between adherent cell culture and suspension cell culture, while cell-free, egg-based, and synthetic peptide platforms introduce their own scale-up and analytical challenges.

Service offering segmentation reveals varying levels of integration and margin potential, with analytical services, drug substance manufacturing, fill-finish, formulation services, logistics, and packaging each demanding specific capabilities and quality systems. Application type differentiation into preventive and therapeutic vaccines influences batch release strategies, potency assays, and post-market surveillance approaches. Application stage is also material to partner selection: clinical-stage programs-spanning Phase I, Phase II, and Phase III studies-require flexible manufacturing and rapid change control, whereas commercial-stage programs demand validated capacity, sustained supply agreements, and mature quality management systems. Finally, end-user categories-biotech companies, government agencies, and pharmaceutical companies-bring differing procurement behaviors, risk tolerances, and contracting preferences, which in turn shape the structure of commercial contracts and technical transfer expectations.

Regional capacity, regulatory diversity, and supply chain corridors that determine where vaccine manufacturing investments yield strategic resilience and commercial advantage

Regional dynamics determine where investments in capacity and capability will deliver the greatest strategic returns. The Americas prioritize rapid access to advanced biologics platforms and tend to favor partnerships that compress development timelines through co-located technical teams and robust analytics. Regulatory pathways in the region emphasize alignment with international standards and often support accelerated access for priority programs, which in turn incentivizes local manufacturing and advanced fill-finish capabilities.

Europe, Middle East & Africa present a diverse regulatory and commercial tapestry that rewards flexible, regionally distributed manufacturing footprints. In these regions, harmonization efforts and cross-border procurement programs make strategic collaboration attractive, particularly when governments and agencies seek to build resilience. Asia-Pacific is characterized by a mix of high-capacity industrial infrastructure and emerging localized innovation hubs; market participants there emphasize scalable platforms, cost-efficient production, and increasingly sophisticated contract development and manufacturing organizations. Transitioning from regional analysis to action requires an appreciation for how local regulatory expectations, workforce availability, and logistics corridors intersect with technology selection and long-term supply agreements.

Strategic behaviors, capability investments, and partnership models that distinguish high-performing contract manufacturers and service providers in vaccine production

Competitive dynamics among companies operating in the contract vaccine manufacturing space are shaped by strategic investments in vertical integration, platform specialization, and service breadth. Leading organizations are differentiating by embedding analytical services and development expertise to reduce technical transfer friction and shorten time-to-clinic. Others emphasize modular capacity and flexible single-use manufacturing to serve a broader set of modalities without extensive retooling. Alliances and strategic partnerships-ranging from capacity-sharing agreements to technology licensing and joint venture models-are common mechanisms for closing capability gaps and accelerating access to new geographies.

At the capability level, firms that demonstrate consistent quality performance in fill-finish, robust cold chain logistics, and validated formulation approaches secure preferential contracting with large sponsors and public purchasers. Investment in digital quality systems and data integrity frameworks has become a non-negotiable differentiator, enabling remote audits and streamlined regulatory interactions. From a commercial posture, organizations offering tailored contracting terms-such as flexible capacity reservation, milestone-based payments, and shared-risk models-tend to win programs where speed and predictability are equally valued. The competitive landscape thus rewards not only technical excellence but also commercial creativity and operational transparency.

Actionable recommendations for aligning technical capability, supply chain resilience, contracting models, and regional engagement to accelerate vaccine program success

To translate insight into competitive advantage, industry leaders should focus on targeted, actionable steps that reduce program risk and accelerate commercial progress. First, prioritize capability alignment by matching vaccine modality and development stage with partner specialization; this reduces technical transfer time and minimizes rework during scale-up. Next, strengthen supply chain robustness by qualifying multiple suppliers for critical raw materials and single-use components, and by developing contingency plans that include regional sourcing and inventory buffers.

Operationally, invest in modular facility designs and automation in fill-finish to increase throughput without proportionate increases in footprint or headcount. From a commercial perspective, structure contracts that balance flexibility and predictability-combining capacity reservations with performance-based milestones. Leaders should also invest in analytics and digital quality systems to enable remote oversight, faster batch release, and smoother regulatory submissions. Finally, pursue selective partnerships with local stakeholders in priority regions to reduce tariff exposure and accelerate market entry. Implementing these recommendations will require cross-functional coordination between R&D, supply chain, quality, and commercial teams, but doing so yields measurable improvements in program resilience and time-to-market.

Transparent mixed-methods research design combining primary stakeholder interviews, regulatory and technical evidence, and cross-validated synthesis to inform strategic decisions

The research underpinning these insights uses a mixed-methods approach designed to triangulate evidence from multiple data sources and stakeholder perspectives. Primary data were collected through structured interviews with senior leaders across contract manufacturing organizations, vaccine developers, regulatory advisors, and procurement authorities to capture operational realities and strategic priorities. Secondary sources included peer-reviewed literature, regulatory guidance documents, patent landscapes, and company technical disclosures to validate technological trends and capability claims.

Analytical rigor was achieved through cross-validation of qualitative inputs with process-level evidence, such as standard operating procedures, regulatory filing templates, and technology transfer case studies. Data quality safeguards included interview coding, methodological transparency, and the exclusion of claims that could not be corroborated with at least two independent sources. The approach emphasizes reproducibility and traceability so that conclusions about segmentation, regional dynamics, and tariff impacts can be followed from raw inputs through synthesis to executive recommendations. This methodology provides decision-makers with a defensible basis for procurement, capacity planning, and partnership selection.

Synthesis of strategic imperatives demonstrating how integrated capability design, supply chain resilience, and partnership alignment determine program and public health outcomes

The converging forces of technological innovation, regulatory modernization, and geopolitical pressure have redefined the priorities for vaccine contract manufacturing. Organizations that succeed will be those that combine platform-specific technical excellence with integrated service offerings, robust supply chain strategies, and regionally informed investment choices. The analysis highlights the importance of aligning modality requirements-from mRNA and viral vectors to protein-based platforms-with the appropriate manufacturing architectures and analytics capabilities, while also accounting for the realities of procurement behavior across biotech firms, government bodies, and pharmaceutical companies.

In sum, the path to resilient and efficient vaccine manufacturing lies in a balanced strategy that mitigates tariff and supply chain volatility, leverages flexible and automated production capacity, and cultivates transparent commercial partnerships. Executives should view contract manufacturing as a strategic capability to be designed, not merely purchased. By taking a deliberate, integrated approach to partner selection and capability investment, organizations can reduce program risk, compress development timelines, and improve the predictability of product supply to patients and public health systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Growing demand for mRNA vaccine contract manufacturing capacity accelerated by pandemic preparedness strategies
  • 5.2. Increasing partnerships between biotech firms and CMOs to scale up personalized cancer vaccine production pipelines
  • 5.3. Adoption of single-use bioreactor technologies to enhance flexibility and reduce cross-contamination risks in vaccine manufacturing
  • 5.4. Regulatory harmonization efforts streamlining quality and compliance requirements across major vaccine production jurisdictions
  • 5.5. Investment surge in fill-finish capabilities to address global shortages of vials and syringes and expedite vaccine distribution
  • 5.6. Integration of digital twins and real-time analytics for process optimization and predictive maintenance in vaccine CMO facilities

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Vaccine Contract Manufacturing Market, by Vaccine Type

  • 8.1. DNA
  • 8.2. Inactivated
  • 8.3. Live Attenuated
  • 8.4. MRNA
  • 8.5. Toxoid
  • 8.6. Viral Vector

9. Vaccine Contract Manufacturing Market, by Technology Platform

  • 9.1. Cell Based
    • 9.1.1. Adherent Cell Culture
    • 9.1.2. Suspension Cell Culture
  • 9.2. Cell Free
  • 9.3. Egg Based
  • 9.4. Synthetic Peptide

10. Vaccine Contract Manufacturing Market, by Service Offering

  • 10.1. Analytical Services
  • 10.2. Drug Substance Manufacturing
  • 10.3. Fill Finish
  • 10.4. Formulation Services
  • 10.5. Logistics
  • 10.6. Packaging

11. Vaccine Contract Manufacturing Market, by Application Type

  • 11.1. Preventive Vaccines
  • 11.2. Therapeutic Vaccines

12. Vaccine Contract Manufacturing Market, by Application Stage

  • 12.1. Clinical Stage
    • 12.1.1. Phase I
    • 12.1.2. Phase Ii
    • 12.1.3. Phase Iii
  • 12.2. Commercial Stage

13. Vaccine Contract Manufacturing Market, by End User

  • 13.1. Biotech Companies
  • 13.2. Government Agencies
  • 13.3. Pharmaceutical Companies

14. Vaccine Contract Manufacturing Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Vaccine Contract Manufacturing Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Vaccine Contract Manufacturing Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. AbbVie Inc
    • 17.3.2. Ajinomoto Co., Inc.
    • 17.3.3. Aton (Shanghai) Biotech Co., Ltd.
    • 17.3.4. Avid Bioservices, Inc.
    • 17.3.5. Catalent, Inc.
    • 17.3.6. Charles River Laboratories International, Inc.
    • 17.3.7. CSL Limited
    • 17.3.8. Curia Global, Inc.
    • 17.3.9. Cytovance Biologics by Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
    • 17.3.10. Emergent BioSolutions Inc.
    • 17.3.11. FUJIFILM Diosynth Biotechnologies U.S.A., Inc. by FUJIFILM Corporation
    • 17.3.12. Gedeon Richter PLC
    • 17.3.13. GlaxoSmithKline PLC
    • 17.3.14. ICON PLC
    • 17.3.15. IDT Biologika GmbH
    • 17.3.16. KBI Biopharma, Inc. by JSR Corporation
    • 17.3.17. Klocke Pharma-Service GmbH
    • 17.3.18. Lonza Group Ltd.
    • 17.3.19. Merck KGaA
    • 17.3.20. Moderna, Inc.
    • 17.3.21. Pfizer Inc.
    • 17.3.22. Pharmaceutical Product Development by Thermo Fisher Scientific Inc.
    • 17.3.23. Recipharm AB
    • 17.3.24. Serum Institute of India
    • 17.3.25. Vetter Pharma-Fertigung GmbH & Co. KG

LIST OF FIGURES

  • FIGURE 1. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. VACCINE CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. VACCINE CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. VACCINE CONTRACT MANUFACTURING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY INACTIVATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY INACTIVATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY MRNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY MRNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY MRNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY MRNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY MRNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY MRNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TOXOID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TOXOID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TOXOID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TOXOID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TOXOID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TOXOID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY ADHERENT CELL CULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY ADHERENT CELL CULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY ADHERENT CELL CULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY ADHERENT CELL CULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY ADHERENT CELL CULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY ADHERENT CELL CULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SUSPENSION CELL CULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SUSPENSION CELL CULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SUSPENSION CELL CULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SUSPENSION CELL CULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SUSPENSION CELL CULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SUSPENSION CELL CULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL FREE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL FREE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL FREE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL FREE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL FREE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL FREE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY EGG BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY EGG BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY EGG BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY EGG BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY EGG BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY EGG BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SYNTHETIC PEPTIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SYNTHETIC PEPTIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SYNTHETIC PEPTIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SYNTHETIC PEPTIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SYNTHETIC PEPTIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SYNTHETIC PEPTIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DRUG SUBSTANCE MANUFACTURING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DRUG SUBSTANCE MANUFACTURING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DRUG SUBSTANCE MANUFACTURING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DRUG SUBSTANCE MANUFACTURING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DRUG SUBSTANCE MANUFACTURING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DRUG SUBSTANCE MANUFACTURING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FILL FINISH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FILL FINISH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FILL FINISH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FILL FINISH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FILL FINISH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FILL FINISH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY LOGISTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY LOGISTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY LOGISTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY LOGISTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY LOGISTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY LOGISTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PREVENTIVE VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PREVENTIVE VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PREVENTIVE VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PREVENTIVE VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PREVENTIVE VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PREVENTIVE VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHASE I, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHASE I, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHASE I, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHASE I, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHASE I, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHASE II, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHASE II, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHASE II, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHASE II, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHASE II, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHASE III, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHASE III, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHASE III, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHASE III, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHASE III, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL STAGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL STAGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL STAGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL STAGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL STAGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL STAGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY BIOTECH COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY BIOTECH COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY BIOTECH COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY BIOTECH COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY BIOTECH COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY BIOTECH COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY GOVERNMENT AGENCIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY GOVERNMENT AGENCIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY GOVERNMENT AGENCIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY GOVERNMENT AGENCIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY GOVERNMENT AGENCIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY GOVERNMENT AGENCIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. MIDDLE EAST VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. MIDDLE EAST VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. MIDDLE EAST VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. MIDDLE EAST VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 286. MIDDLE EAST VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 287. MIDDLE EAST VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2024 (USD MILLION)
  • TABLE 288. MIDDLE EAST VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2025-2032 (USD MILLION)
  • TABLE 289. MIDDLE EAST VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2024 (USD MILLION)
  • TABLE 290. MIDDLE EAST VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2025-2032 (USD MILLION)
  • TABLE 291. MIDDLE EAST VACCINE CONTRACT MANUFACTURING MARKET SIZE,